TXMDNasdaq

TherapeuticsMD, Inc.

Healthcare·Pain·Commercial·Boca Raton, FL, United States
PainReproductive

TherapeuticsMD, Inc. (TXMD): 3 pipeline candidates · 3 upcoming catalysts · ~22 mo cash runway. Updated within the last hour.

7.3/10

BioSniper Score

6-factor signal · derived from public data

Cash Runway6.0

21.7 months

Financial Health9.4

D/E 0.39 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst Momentum6.0

3 upcoming, next in ~2348d

Insider Signal6.5

1 buy · 0 sells (180d)

A transparent, data-derived signal for TherapeuticsMD, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$26.3M

Cash

$8.4M

Quarterly Burn

$1.4M

Runway

21.7 mo

Revenue

$724K

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~Apr 2028
Today~172 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (3 candidates)

Upcoming Catalysts (3)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

47

Total value held

$4.8M

HolderSharesValue
vanguard capital management llc707,394$1.4M
clearline capital lp635,222$1.3M
adar1 capital management, llc209,210$423K
renaissance technologies llc146,200$295K
morgan stanley129,217$261K
blackrock, inc.115,145$233K
geode capital management, llc109,817$222K
citadel advisors llc95,114$192K
vanguard fiduciary trust co63,831$129K
state street corp30,100$61K

Showing top 10 of 47 institutional holders of TherapeuticsMD, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Marlan D. Walker J.D.

Frequently asked questions

How many drug candidates are in TherapeuticsMD, Inc.'s pipeline?

TherapeuticsMD, Inc. (TXMD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is TherapeuticsMD, Inc.'s lead drug candidate?

TherapeuticsMD, Inc.'s most advanced tracked candidate is annovera (Approved) for prevent pregnancy.

What is TherapeuticsMD, Inc.'s next catalyst?

TherapeuticsMD, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: BIJUVA" — expected November 21, 2032.

What is TherapeuticsMD, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, TherapeuticsMD, Inc. has approximately 21.7 months of cash runway.

What is TherapeuticsMD, Inc.'s market capitalization?

TherapeuticsMD, Inc.'s market capitalization is approximately $26.3M.

Get the full picture on TherapeuticsMD, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.